"HuiLiao Biologicals Honored on the "2025 China Rising Future Unicorns List"

Recently, the much-anticipated "2025 China Rising Future Unicorns List" was officially released, with HuiLiao Biologicals being named among the honorees. This list was curated by Pencil News, which organized a panel of approximately 200 industry experts to conduct research based on data support from Pencil News DATA, Wind, DZH Enterprise Early Warning System, and Qichacha. After a comprehensive evaluation of targeted capitalization potential and market potential, the final list was determined. A total of 97 outstanding technology companies were included in the 2025 China Rising Future Unicorns List, with HuiLiao Biologicals being the only enterprise focused on mRNA vaccine development.

This selection not only highlights HuiLiao Biologicals' exceptional innovative capabilities in the field of mRNA vaccine research and development but also signifies the company's broad development prospects and sustainable industrial application capabilities. Furthermore, it underscores the immense potential of mRNA vaccines for future applications and their limitless possibilities in the prevention of infectious diseases.

In the future, HuiLiao Biologicals will continue to deepen the technological innovation of mRNA vaccines. Building on its independently developed CLS/LNP "dual-wheel" delivery system platform, the company aims to optimize mRNA sequence design and develop safer and more efficient mRNA vaccines. This will enable mRNA vaccines to benefit a wider range of fields. Additionally, HuiLiao Biologicals will provide cost-effective innovative mRNA vaccine solutions for veterinary use, supporting agricultural development and contributing to the high-quality growth of the global livestock industry and the broader biopharmaceutical and healthcare sectors.

About Suzhou Huiliao

Suzhou Huiliao Biotechnology is a high-tech enterprise engaged in the comprehensive provision of nucleic acid drug industrialization. The company's business spans the research and production of mRNA drugs, clinical trial design, data analysis, and other areas, with a focus on the development of mRNA technology-based infectious disease vaccines, cancer vaccines, cell therapies, protein replacements, and more.